This $1,061,189 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research conducted by the Regents of the University of Michigan to investigate immune crosstalk in lung injury and fibrosis. The key goals of the research are to:
-
Study how epithelial cell-derived heparin-binding EGF-like growth factor (HB-EGF) regulates fibrosis and interacts with myeloid cells.
-
Uncover mechanisms behind impaired innate immunity against gram-positive bacterial infections in lung fibrosis.
-
Test delivery of cyclooxygenase inhibitors or EP2 antagonists using dextran nanoparticles to target phagocytes in the lung.
-
Examine how structural cell expression of TLR9 regulates myeloid cell function in clearing bacterial infections post-influenza.
This 7-year award aims to provide new insights into lung disease pathogenesis and identify potential therapeutic interventions. The award also supports continued mentorship of trainees and faculty by the principal investigator.
Generated 2/25/25, 5:17 AM